Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032

Description

Peripheral T-cell lymphoma (PTCL) remains universally hard to treat in both the frontline and relapsed settings. The International PTCL Project reported 5-year OS for PTCL-NOS, AITL, ALK-negative ALCL, and ALK-positive ALCL to be 32%, 32%, 49%, and 70%, respectively. Clinical studies adding active agents to the CHOP regimen have shown limited efficacy improvements, demonstrating the high unmet need in these patients.

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas representing 5% to 15% of non-Hodgkin’s lymphomas (NHL) in the Western world. It is composed of peripheral (systemic) and cutaneous forms developed from T cells and natural killer (NK) cells. Clinically, these lymphomas are often aggressive. The standard of care for the last 30 years has been cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with or without additional etoposide (CHOEP). A meta-analysis of the outcome of PTCL treated with anthracycline-based regimens demonstrated a 5-year overall survival of only 36.6%. Attempts have been made to improve on this poor outlook by: (i) adding newer drugs to the CHOP backbone (alemtuzumab, romidepsin, brentuximab vedotin); (ii) intensifying the regimen (DA-EPOCH); (iii) developing alternative regimens (eg, gemcitabine-based combinations).

Peripheral T-cell lymphoma (PTCL) Epidemiology

The most recent WHO 2016 Classification of Tumors of Hematopoietic and Lymphoid Tissues, now recognizes 29 discrete types of PTCL. The most common subtypes account for over one-half of all PTCL cases, including PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-positive or ALK-negative anaplastic large cell lymphoma (ALCL). PTCL is challenging to diagnose, largely owing to a lack of reliable diagnostic markers and limited clinical experience because of the rarity of the disease, which may lead to patients receiving inadequate or delayed treatment.

Peripheral T-cell lymphoma (PTCL) Market Forecast

The Peripheral T-cell lymphoma therapy market is expected to experience high growth throughout our study period, estimated to reach $1.9 billion by 2030, representing 15.2 % annual growth. Brentuximab vedotin is already approved for first-line PTCL setting especially in systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL) [100% CD30 expression rate], including angioimmunoblastic T-cell lymphoma [75% CD30 expression rate] and PTCL not otherwise specified [60% CD30 Expression rate], in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).

KOLs indicated that CD30 expression levels would be the other major factor driving the uptake of Adcetris + CHP. Given the uncommon nature of the disease, research into Cd30 expression hasn’t been extensive—especially as it didn’t impact Chop treatment. Current estimates have placed the level of Cd30 expression somewhere between one-third to ~40% of all PTCL. However, given that the threshold level for Adcetris activity might be very low, with some patients expressing very low levels of CD30, up to 50% of all newly diagnosed individuals could be eligible for treatment.

There is currently no standard therapy for relapsed/refractory PTCL Patients. Despite some PTCL patients having initial responses to chemotherapy, most patients either relapse or fail to achieve remission. A few agents have been approved for relapsed PTCL.

Nevertheless, the response rates for most agents are low and the response durations are not sustained, which leads to eventual relapse. The growth of the ALL market through the forecast period will be driven by emerging therapies Darinaparsin (Solasia), Tipifarnib (Kura Oncology), AFM13 (Affimed), AUTO4 (Autolus), and others. Many new therapies currently in development are expected to be approved during our forecast period of 2022-2032. Emerging therapies are mostly focused on eliminating or reducing unmet needs like the requirements for much more effective treatments for the relapsed/refractory cases of PTCL. Launching these upcoming therapies tends to increase the market size of Peripheral T-Cell Lymphoma (PTCL) in upcoming years.

Report Highlights

• Peripheral T-cell lymphoma (PTCL) Current Market Trends
• Peripheral T-cell lymphoma (PTCL) Current & Forecasted Cases across the G7 Countries
• Peripheral T-cell lymphoma (PTCL) Market Opportunities And Sales Potential for Agents
• Peripheral T-cell lymphoma (PTCL) Patient-based Market Forecast to 2030
• Peripheral T-cell lymphoma (PTCL) Untapped Business Opportunities
• Peripheral T-cell lymphoma (PTCL) Product Positioning Vis-a-vis Competitors’ Products
• Peripheral T-cell lymphoma (PTCL) KOLs Insight